IP Library Granted Patent US 10,994,007
Granted Patent B2
US 10,994,007 · App. 15/363,748 · Granted May 4, 2021

Immunity inducer

Inventors: Hiroshi Handa (Tokyo, JP); Masaaki Kawano (Saitama, JP); Masahiko Kato (Kobe, JP)
Assignees: Saitama Medical University; SYSMEX CORPORATION
A61K39/39C07K14/005C12N7/00A61K2039/5256A61K2039/5258A61K2039/54A61K2039/542A61K2039/543A61K2039/572A61K2039/575C07K2319/00C07K2319/43C12N2710/22023C12N2710/22034C12N2760/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,994,007
App. No.
15/363,748
Granted
May 4, 2021
Kind
B2
Abstract

Disclosed is an immunity inducer. The immunity inducer comprises virus like particles; the virus like particles comprise a virus-derived outer coat protein and an antigen-bound protein comprising an exogenous antigen; the outer coat protein constitutes an outer coat of the virus like particles, and the antigen-bound protein is comprised in the outer coat; and the virus like particles induce an immune effect of a living body on the antigen.

Claims (34)

1. A method of inducing immunity of a living body;

comprising:

(1) administering a pharmacologically effective amount of an immunity inducer to the living body, and

(2) inducing in said living body, by said administration, an immune response against the exogenous antigen,

wherein the immunity inducer comprises virus like particles;

wherein the virus like particles comprise an outer coat protein constituting an outer coat of the virus like particles, and further comprise an antigen-bound protein comprising an exogenous antigen, wherein the virus like particles are virus like particles in which the amino acid sequence of the exogenous antigen is not inserted within the amino acid sequence of the outer coat protein, but the exogenous antigen is present inside the outer coat, and

wherein the administering step is conducted by oral administration, transmucosal administration, parenteral administration, or transdermal administration,

wherein the exogenous antigen is selected from the group consisting of: antigens from pathogens; and cancer antigens,

wherein the exogenous antigen is not exposed on the outer surface of said virus like particles,

wherein in the inducing step, a CTL and an antibody against the exogenous antigen are induced,

wherein the outer coat protein is VP1 of SV40, and

wherein the antigen-bound protein is a fusion protein of the exogenous antigen and an inner peptide, and the inner peptide is VP2 of SV40 and/or VP3 of SV40.

2. The method according to claim 1 , wherein the amino acid sequence of the inner peptide comprises the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 11.

3. The method according to claim 1 , wherein the immunity inducer is a solid preparation, a semisolid preparation, a liquid preparation, an injection, or a suppository.

4. The method according to claim 1 , wherein the amino acid sequence of the VP1 comprises the amino acid sequence of SEQ ID NO: 2.

5. The method according to claim 1 , wherein

the amino acid sequence of the VP1 comprises the amino acid sequence of SEQ ID NO: 2,

the amino acid sequence of the VP2 comprises the amino acid sequence of SEQ ID NO: 11, and

the amino acid sequence of the VP3 comprises the amino acid sequence of SEQ ID NO: 9.

6. A method of inducing immunity of a living body; comprising:

(1) administering a pharmacologically effective amount of an immunity inducer to the living body, and

(2) inducing in said living body, by said administration, an immune response against the exogenous antigen,

wherein the immunity inducer comprises virus like particles;

wherein the virus like particles comprise an outer coat protein constituting an outer coat of the virus like particles, and further comprise an antigen-bound protein comprising an exogenous antigen, wherein the virus like particles are virus like particles in which the amino acid sequence of the exogenous antigen is not inserted within the amino acid sequence of the outer coat protein, but the exogenous antigen is present inside the outer coat, and

wherein the administering step is conducted by oral administration, transmucosal administration, parenteral administration, or transdermal administration,

wherein the exogenous antigen is selected from the group consisting of: antigens from pathogens; and cancer antigens,

wherein the exogenous antigen is not exposed on the outer surface of said virus like particles,

wherein in the inducing step, a CTL and an antibody against the exogenous antigen are induced,

wherein the outer coat protein is VP1 of SV40, and

wherein the antigen-bound protein is a fusion protein of the exogenous antigen and an inner peptide, and the inner peptide is VP2 of SV40.

7. The method according to claim 6 , wherein the amino acid sequence of the VP1 comprises the amino acid sequence of SEQ ID NO: 2.

8. The method according to claim 6 , wherein

the amino acid sequence of the VP1 comprises the amino acid sequence of SEQ ID NO: 2, and

the amino acid sequence of the VP2 comprises the amino acid sequence of SEQ ID NO: 11.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2016
From: KAWANO, MASAAKI; KATO, MASAHIKO
To: SAITAMA MEDICAL UNIVERSITY; SYSMEX CORPORATION
Reel/Frame 040466/0577 →
Priority Claims (1)
JP JP2015-234206 · Nov 30, 2015 · national
Continuity (1)
Related Publication 20170151326A1 · Jun 1, 2017